MannKind Revenue 2006-2021 | MNKD

MannKind revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
MannKind Annual Revenue
(Millions of US $)
2020 $65
2019 $63
2018 $28
2017 $12
2016 $175
2015 $
2014 $
2013 $
2012 $0
2011 $0
2010 $0
2009 $
2008 $0
2007 $0
2006 $0
2005 $
MannKind Quarterly Revenue
(Millions of US $)
2021-06-30 $23
2021-03-31 $17
2020-12-31 $18
2020-09-30 $15
2020-06-30 $15
2020-03-31 $16
2019-12-31 $16
2019-09-30 $15
2019-06-30 $15
2019-03-31 $17
2018-12-31 $16
2018-09-30 $4
2018-06-30 $4
2018-03-31 $3
2017-12-31 $5
2017-09-30 $2
2017-06-30 $2
2017-03-31 $3
2016-12-31 $12
2016-09-30 $162
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30 $0
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31 $0
2010-12-31
2010-09-30
2010-06-30 $0
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
2008-12-31
2008-09-30
2008-06-30
2008-03-31 $0
2007-12-31
2007-09-30
2007-06-30
2007-03-31 $0
2006-12-31
2006-09-30
2006-06-30
2006-03-31 $0
2005-12-31
2005-09-30
2005-06-30
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.036B $0.065B
Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43